Zymergen, Inc. (ZY)
|Net Income (ttm)||n/a|
|Trading Day||June 17|
|Day's Range||44.00 - 45.50|
|52-Week Range||25.75 - 52.00|
EMERYVILLE, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Biofacturing leader Zymergen today announced the company will be participating in the upcoming Goldman Sachs Annual Global Healthcare Virtual Confer...
SEATTLE--(BUSINESS WIRE)--Accelerator Life Science Partners (“ALSP”), a leading early-stage life science accelerator and investment firm, today announced that its portfolio company, Lodo Therapeutics Co...
Here's a quick look at some earnings reports that were released after markets closed on Monday or before Tuesday's opening bell.
EMERYVILLE, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen”), one of the world's leading biofacturing companies, today reported preliminary financial results for the first quarter end...
As if to underscore the shrinking number of earnings reports now trickling rather than pouring out of U.S.
EMERYVILLE, Calif., May 21, 2021 (GLOBE NEWSWIRE) -- Biofacturing leader Zymergen today announced the company will be participating in the upcoming UBS Global Healthcare Virtual Conference.
Less than a month ago, Zymergen Inc. (NASDAQ: ZY) came public, raising $500 million in an upsized traditional IPO.
EMERYVILLE, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Biofacturing leader Zymergen, today announced it will report financial results for the first quarter 2021 after market close on Monday, May 24th, 202...
Here's what to look for and what to steer clear of.
The synthetic biology upstart will have enough cash to hit the ground running.
Zymergen Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purcha...
EMERYVILLE, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen”), one of the world's foremost biofacturing companies, today announced the closing of its initial public offering of 18,54...
"I love the symbolism that we're going public on Earth Day," says Zymergen's Josh Hoffman. The synthetic biology company raised $500 million in an IPO set to value the company at more than $3 billion.
EMERYVILLE, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen”), one of the world's foremost biofacturing companies, today announced the pricing of its initial public offering of 16,13...
This week's offerings don't have quite the same high profile as last week's highly anticipated IPO of Coinbase Global (NASDAQ: COIN). Nevertheless, there are several exciting IPOs that investors should ...
Zymergen Inc. (“Zymergen”), one of the world’s foremost biofacturing companies, today announced...
Zymergen Inc, backed by SoftBank Group Corp Inc's Vision Fund, is looking to raise around $100 million through an initial public offering in the United States, according to a regulatory filing on T...
Zymergen, Inc. has filed to go public with an IPO on the NASDAQ.
Zymergen partners with Nature to design, develop, and commercialize bio-based breakthrough products that deliver extraordinary value to customers in a broad range of industries. Our first innovations include films designed for electronics companies to use in new categories of smart devices, including rollable tablets and naturally derived UV protection. We create new products with a proprietary platform that unlocks the design and manufacturing efficiency of biological processes with technology’s ability to rapidly iterate and control diverse... [Read more...]
|IPO Date |
Apr 22, 2021
|Stock Exchange |
|Ticker Symbol |
In 2020, Zymergen's revenue was $13.28 million, a decrease of -13.85% compared to the previous year's $15.42 million. Losses were -$262.19 million, 10.7% more than in 2019.